Metabolic syndrome and angiotensin II receptor antagonists

Metabolic syndrome and angiotensin II receptor antagonists

Aim. To investigate the effects of angiotensin II receptor antagonist irbesartan on blood pressure (BP), tissue insulin sensitivity, carbohydrate and lipid metabolism, cerebral perfusion parameters in patients with arterial hypertension (AH), metabolic syndrome (MS), and Type 2 diabetes mellitus (DM...

Full description

Bibliographic Details
Main Authors:	K. M. Mamyrbayeva, V. B. Mychka, V. B. Sergienko, I. E. Chazova
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2007-04-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	arterial hypertension metabolic syndrome diabetes mellitus irbesartan
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1191

Similar Items

Arterial hypertension and Type 2 diabetes mellitus: any benefits for angiotensin II receptor blockers?
by: V. V. Fomin, et al.
Published: (2007-06-01)

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN
by: V. V. Fomin
Published: (2013-08-01)

Left ventricular hypertrophy: prognostic value, pathogenesis, possible remodeling: focusing on angiotensin receptor antagonists
by: M. D. Smirnova, et al.
Published: (2007-12-01)

Cerebrovascular events primary prevention in metabolic syndrome patients
by: V. B. Mychka, et al.
Published: (2006-04-01)

Obesity pharmaceutical correction in metabolic syndrome patients
by: V. B. Mychka, et al.
Published: (2005-08-01)

Metabolic syndrome treatment: focusing on acarbose
by: I. E. Chazova, et al.
Published: (2008-04-01)

Possible combinations of antihypertensive drugs at treatment of arterial hypertension at patientswith metabolic syndrome
by: Viktoriya Borisovna Mychka, et al.
Published: (2009-03-01)

Imidazoline receptor agonist moxonidine and arterial hypertension treatment in women with menopausal metabolic syndrome
by: E. V. Tishina, et al.
Published: (2011-06-01)

Fixed dose combination of perindopril with indapamide in primary prevention of cerebrovascular complications among patients with metabolic syndrome and arterial hypertension
by: V. B. Mychka, et al.
Published: (2006-02-01)

IRBESARTAN IN THE CLINICAL PRACTICE
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

Prevalence of metabolic syndrome and its components in patients with arterial hypertension and obesity
by: I. E. Chazova, et al.
Published: (2005-12-01)

Combined therapy in metabolic syndrome treatment
by: Yu. V. Zhernakova, et al.
Published: (2010-08-01)

ANGIOTENSIN RECEPTOR ANTAGONISTS: GOING WITH THE TIMES
by: E. O. Taratukhin
Published: (2013-06-01)

Perindopril metabolic effects and organo-protective action in metabolic syndrome patients
by: V. B. Mychka, et al.
Published: (2007-04-01)

Benefits of vasodilating beta-adrenoblockers for arterial hypertension treatment
by: V. B. Mychka
Published: (2012-06-01)

The effect of the <i>M235T</i> polymorphism of the angiotensinogen gene on the office blood pressure during therapy with angiotensin II receptor blockers
by: E. V. Rebrova, et al.
Published: (2024-12-01)

Beta-adrenoblockers in patients with metabolic syndrome
by: V. B. Mychka, et al.
Published: (2008-04-01)

Diuretics in patients with metabolic disturbances
by: I. E. Chazova, et al.
Published: (2007-04-01)

Angiotensin II receptor antagonists – we have moved closer to the patient
by: L. G. Ratova, et al.
Published: (2005-04-01)

Carotid intima-media thickness in arterial hypertension patients with and without metabolic syndrome
by: G. Kh. Sharipova, et al.
Published: (2009-04-01)

Combined antihypertensive therapy in treating patients with metabolic syndrome
by: V. B. Mychka, et al.
Published: (2008-06-01)

Angiotensin II receptor blockers and cardiorenal risk management: Irbesartan status
by: V. V. Fomin
Published: (2013-12-01)

Moxonidine-based combination antihypertensive therapy in patients with metabolic syndrome
by: E. V. Tishina, et al.
Published: (2012-06-01)

Microcirculatory function in patients with arterial hypertension, metabolic syndrome and diabetes mellitus
by: A. P. Vasilyev, et al.
Published: (2008-10-01)

Open, multi-center randomized research and clinical program MINOTAUROS: intermediate data analysis
by: I. E. Chazova, et al.
Published: (2006-04-01)

Heart pathology in patients with arterial hypertension and metabolic syndrome
by: G. Kh. Sharipova, et al.
Published: (2008-12-01)

Intima- media thickness of соmmоn carotid artery in patients with arterial hypertension and present or absent metabolic syndrome
by: G. Kh. Sharipova, et al.
Published: (2008-12-01)

APPROACHES TO SELECTION OF ANTIHYPERTENSION DRUG WITHIN APPLIED LOWER TARGET BLOOD PRESSURE LEVELS
by: S. R. Gilyarevsky, et al.
Published: (2017-12-01)

Comparison of platelet hemostasis effects for angiotensin receptor blockers in patients with arterial hypertension and metabolic syndrome
by: I. N. Medvedev, et al.
Published: (2007-08-01)

Irbesartan attenuates renal injury with diabetic nephropathy rats
by: ZHANG Ya, HUANG Wen-hui, HOU Zhi-min, LIU Ju-xiang, LIU Jing
Published: (2020-04-01)

Metabolic (cytoprotective) therapy of menopausal disturbances
by: S. N. Tolstov, et al.
Published: (2011-06-01)

Direct renin inhibitor aliskiren in women with menopausal metabolic syndrome and arterial hypertension
by: Yu. V. Zhernakova, et al.
Published: (2011-08-01)

PLACE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN ARTERIAL HYPERTENSION THERAPY
by: S. A. Boytsov, et al.
Published: (2016-01-01)

Prevalence of microalbuminuria and its associated cardiovascular risk: German and Swiss results of the recent global i-SEARCH survey
by: U Tebbe, et al.
Published: (2009-08-01)

About INCLUSIVE study
by: G. Pinna
Published: (2013-05-01)

Novel Role of Irbesartan in Elevating Serum High Density Lipoprotein in Hypercholesterolemic Animal Model
by: Sabeen Shakir, et al.
Published: (2024-05-01)

DAMAGE OF RENAL FUNCTION AND DYNAMICS OF DYSLIPIDEMIA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WITH INSUFFICIENT GLYCEMIC COMPENSATION UNDER CONDITION OF CORRECTION OF HYPERTENSION WITH ANGIOTENSIN II RECEPTOR ANTAGONISTS
by: N.O. Pertseva
Published: (2014-12-01)

Gene polymorphism of endothelial NO-synthase, angiotensin-converting enzyme and receptors of angiotensin II type 1 in patients with coronary artery disease and type II diabetes
by: Yakovleva L.M.
Published: (2013-12-01)

Interaction between dipeptidyl-peptidase-4 inhibitors and drugs acting on renin angiotensin aldosterone system for the risk of angioedema: a pharmacovigilance assessment using disproportionality and interaction analyses
by: Kannan Sridharan, et al.
Published: (2025-01-01)

Difficult choice: angiotensin receptor antagonists
by: E. O. Taratukhin
Published: (2013-04-01)